Physician profile
Eugene Kalmuk
NPI 1114912367
$2,835.06
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $1,028 · 2023: $17.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $443.97 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $436.59 | 2019-2020 | |
| Novo Nordisk INC | $341.69 | 2019-2020 | |
| Astellas Pharma US INC | $223.05 | 2019-2020 | |
| Pfizer INC. | $186.74 | 2019-2020 | |
| Amarin Pharma, INC. | $158.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $105.29 | 2019-2020 | |
| Abbvie INC. | $97.51 | 2019-2020 | |
| Lilly USA, LLC | $97.32 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.33 | 2019-2020 | |
| Amgen INC. | $84.79 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $81.70 | 2019-2020 | |
| Daiichi Sankyo INC. | $65.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.83 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54.81 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $40.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.60 | 2019 | |
| Alfasigma USA, INC. | $25.89 | 2020 | |
| Abbott Laboratories | $18.22 | 2020 | |
| Esperion Therapeutics, INC. | $16.51 | 2020 | |
| Horizon Therapeutics Plc | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Kalmuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.